Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

NCT06016387 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
LMD

Interventions

DRUG: Tucatinib 150 MG
DRUG: Trastuzumab
DRUG: Capecitabine
RADIATION: Brain & Spinal Radiation

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

[object Object]
[object Object]